Recent breakthroughs with mRNA-based vaccines highlight the potential of lipid-based particles as powerful and versatile delivery vectors for vaccines and gene therapies. Used to measure particle size, stability, zeta potential and particle concentration, light scattering techniques are used extensively in the characterization of lipid nanoparticle and liposome research.
The Zetasizer range of light scattering instruments provides high quality, stability-indicating data for drug molecules and their formulations. Delivering data in a short time frame, the Zetasizer allows you to implement this technique throughout the development pipeline.
This webinar explores the challenges and opportunities drug and vaccine developers are currently facing and explains how the Zetasizer can be used to address these and to optimize your formulations.
Earlier in May, the FDA approved the 100th monoclonal antibody product, marking a significant milestone for this technology. The storied successes of the anti-PD-1 and anti-PD-L1 immune checkpoint inhibitor drugs have proven that mAbs demonstrate an excellent ability to recognize cell-surface receptors on cancer cells.
Monoclonal antibodies can be further enhanced by delivering cytotoxic cells or payloads to their intended target. Bispecific antibodies and antibody drug conjugates are two techniques that achieve this goal and are intensely investigated regarding their binding kinetics, stability, and immunogenicity as clinical trials move towards approval.
Date recorded: July 29 202